Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI?

On August 17, OmniAb, Inc. (NASDAQ:OABI) unveiled a global partnership and licensing agreement with Eli Lilly and Company (NYSE:LLY) to jointly discover and develop innovative ion channel therapeutics. In exchange for an upfront sum, potential development and commercialization milestones up to $370 million, and tiered sales royalties, Lilly will receive exclusive global distribution rights.

Although the specific therapeutic target has not been disclosed, the collaboration connects a small-cap discovery platform with a mega-cap pharmaceutical giant. When analyzing their latest financial profiles, stark differences in scale, momentum, and risk become apparent. Eli Lilly (NYSE:LLY) is a dominant force in the healthcare industry, experiencing robust financial growth and commercial expansion.

In Q2 2026, Lilly reported $23 billion in revenue, a 48% increase year-over-year, driven by the popularity of its GLP-1 therapies, Mounjaro and Zepbound. Non-GAAP earnings exceeded estimates at $8.38 per share, prompting Lilly to raise its full-year 2026 revenue guidance to $85.0–$87.0 billion. Despite some challenges, such as $3.03 per share in business development expenses, Lilly generated a net quarterly income of $7.09 billion, demonstrating its strong market position.

On the contrary, OmniAb, Inc. (NASDAQ:OABI) operates on a significantly distinct, asset-light model. In Q2 2026, OmniAb posted revenue of $13.4 million, a substantial rise from $3.9 million in Q2 2025, fueled by milestone payments, service income, and instrument sales. Operating expenses remained steady at $20.1 million, narrowing the quarterly net loss to $5.9 million (down from a loss of $15.9 million the previous year).

Management adjusted OmniAb's full-year 2026 revenue guidance to $32–$36 million, aiming to conclude the year with $37–$41 million in cash reserves. While OmniAb is experiencing rapid growth relative to its initial valuation, Eli Lilly's financial performance clearly outshines OmniAb in terms of profitability, cash flow generation, and market maturity.

For Eli Lilly, the positive scenario hinges on its leadership roles in metabolic diseases, oncology, and immunology, coupled with a vast clinical pipeline. Meeting or exceeding the raised revenue guidance ensures sustained demand and mitigates price erosion. Conversely, the negative outlook emphasizes valuation expectations, potential Medicare price negotiations, and increasing competition in the obesity sector.

For OmniAb, the upside potential is contingent upon its high-margin licensing arrangements. With 110 active partnerships and 425 active programs, new collaborations, like the one with Lilly, provide non-dilutive capital and downstream royalty income without the need for expensive late-stage clinical trials. The downside risk is primarily associated with OmniAb's cash burn and micro-cap volatility.

Until their downstream programs enter late-stage commercialization, the company remains unprofitable, leaving it vulnerable to partner pipeline cancellations. Institutional interest in both firms distinctly illustrates the contrasting investment approaches. Eli Lilly retains high institutional backing, with 132 hedge fund holdings in Q1 2026, led by Ken Fisher's Fisher Asset Management ($6.07 billion position, up 5%) and Ken Griffin's Citadel Investment Group.

Meanwhile, OmniAb enjoys niche institutional support, recorded in 20 hedge funds in Q1 2026, including David Salanic's Whitefort Capital ($25.2 million value, representing 6.21% of the portfolio despite a 28% reduced stake) and Eric Bannasch's Cadian Capital ($10.4 million value, up 2%). The partnership between Eli Lilly and OmniAb showcases two fundamentally different strategies for investing in healthcare innovation: purchasing an established commercial leader or speculating on the technology enabler.

Investors should closely monitor Eli Lilly's execution of its raised revenue expectations, supply chain advancements for Mounjaro and Zepbound, and updates on Phase 3 trials for potential new treatments. In contrast, those considering OmniAb should focus on the progression of its 34 clinical-stage programs toward pivotal trials, managing full-year cash burn against its $37–$41 million target, and further updates regarding the initial target validation in the new Lilly partnership.

Although we recognize the potential of OmniAb as an investment, we believe other AI stocks present greater upside potential with lower downside risk. For those seeking an extremely undervalued AI stock with significant benefits from Trump-era tariffs and the onshoring trend, refer to our complimentary report on the optimal short-term AI investment.